As global markets grapple with rising Treasury yields and tepid economic growth, investors are increasingly focused on identifying stocks that may be trading below their intrinsic value. In this environment, a good stock is often characterized by strong fundamentals and the potential for future growth, making it an attractive option for those seeking value amidst market fluctuations.
Name | Current Price | Fair Value (Est) | Discount (Est) |
Trimegah Bangun Persada (IDX:NCKL) | IDR890.00 | IDR1777.58 | 49.9% |
Provident Financial Services (NYSE:PFS) | US$19.03 | US$37.92 | 49.8% |
Western Alliance Bancorporation (NYSE:WAL) | US$84.27 | US$168.24 | 49.9% |
California Resources (NYSE:CRC) | US$52.32 | US$104.35 | 49.9% |
Geovis TechnologyLtd (SHSE:688568) | CN¥40.77 | CN¥81.16 | 49.8% |
Beyout Investment Group Holding Company - K.S.C. (Holding) (KWSE:BEYOUT) | KWD0.395 | KWD0.79 | 49.9% |
Acerinox (BME:ACX) | €8.52 | €16.98 | 49.8% |
Enento Group Oyj (HLSE:ENENTO) | €18.40 | €36.57 | 49.7% |
ChromaDex (NasdaqCM:CDXC) | US$3.58 | US$7.15 | 49.9% |
Fine Foods & Pharmaceuticals N.T.M (BIT:FF) | €8.36 | €16.70 | 49.9% |
Click here to see the full list of 959 stocks from our Undervalued Stocks Based On Cash Flows screener.
Let's explore several standout options from the results in the screener.
Overview: Grifols, S.A. is a plasma therapeutic company operating in Spain, the United States, Canada, and internationally with a market cap of approximately €6.40 billion.
Operations: Grifols generates revenue primarily from its Biopharma segment (€5.78 billion), followed by the Diagnostic segment (€651.33 million) and Bio Supplies segment (€186.91 million).
Estimated Discount To Fair Value: 47.2%
Grifols appears undervalued, trading at €10.32, significantly below its estimated fair value of €19.55. Despite recent volatility, the company has become profitable this year and is expected to see substantial earnings growth of 28.6% annually over the next three years, outpacing the Spanish market's average growth rate. However, interest payments are not well covered by earnings, which could pose financial challenges despite promising revenue forecasts and strategic product developments like VISTASEAL™ in pediatric surgery.
Overview: IKD Co., Ltd. specializes in the research, development, production, and sale of automotive aluminum alloy precision die castings across the United States, Europe, and Asia with a market cap of CN¥15.13 billion.
Operations: Revenue Segments (in millions of CN¥): The company generates revenue primarily from the sale of automotive aluminum alloy precision die castings in the United States, Europe, and Asia.
Estimated Discount To Fair Value: 13.4%
IKD Co., Ltd. is trading at CN¥15.48, below its estimated fair value of CN¥17.87, with analysts predicting a 51.7% price increase. Recent earnings show a net income rise to CNY 741.79 million for the first nine months of 2024 from CNY 597.61 million last year, reflecting strong revenue growth potential at 23% annually, surpassing the Chinese market average of 13.7%. However, shareholder dilution and low dividend coverage by cash flows present concerns.
Overview: The Shanghai Commercial & Savings Bank, Ltd. operates as a financial institution providing banking services and has a market cap of NT$194.25 billion.
Operations: The company's revenue is primarily derived from its banking segment, amounting to NT$33.16 billion.
Estimated Discount To Fair Value: 17.6%
Shanghai Commercial & Savings Bank is trading at NT$40.05, below its estimated fair value of NT$48.58, indicating potential undervaluation based on cash flows. Despite a drop in recent earnings, with net income for Q2 2024 at TWD 1,468.33 million compared to TWD 5,509.57 million a year ago, the bank's earnings are forecast to grow significantly over the next three years at 32.5% annually—faster than the Taiwanese market average of 19%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BME:GRF SHSE:600933 and TWSE:5876.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。